Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer
To evaluate the efficacy and safety profile of a triplet regimen consisting of gemcitabine, oxaliplatin, and infusional fluorouracil and leucovorin (LV) in advanced pancreatic carcinoma (APC).
Patients and methods
Chemotherapy-naïve patients with histo-/cytologically proven unresectable APC, and bi-dimensionally measurable diseases were eligible. Treatment consisted of fixed-dose rate (10 mg/m2/min) infusion of 800 mg/m2 gemcitabine followed by 2-h infusion of 85 mg/m2 oxaliplatin and then 48-h infusion of fluorouracil and LV (3,000 and 300 mg/m2, respectively) every 2 weeks (the GOFL regimen). The primary end-point was objective response rate.
Forty-five patients were enrolled and received a median of seven [95% confidence interval (CI) 6.4–8.8] cycles of treatment. On intent-to-treat analysis, the overall response and disease-control rates were 33.3% (95% CI 21.4–48.0%) and 68.9% (95% CI 54.8–83.0%), respectively. Clinical benefit response was observed in 46.2% of initially symptomatic patients. The median time-to-tumor progression and overall survival were 5.1 (95% CI 4.0–6.3) months and 8.7 (95% CI, 6.1–11.3) months, respectively. Major grade 3–4 toxicities were neutropenia (28.9%, with 4.4% complicated with fever), peripheral sensory neuropathy (15.6%), nausea/vomiting (13.3%), and diarrhea (6.7%).
The triplet regimen is feasible and exhibits promising activity against APC, deserving further exploration.
KeywordsGemcitabine Oxaliplatin Fluorouracil Pancreatic cancer Phase II
Supported by grants (CA094-PP-04 and CA095-CP-06) from the National Health Research Institutes, Zhunan, Taiwan.
- 4.Heinemann V, Hinke A, Bock S et al (2007) Gemcitabine-based combinations (gem + x) vs Gemcitabine (gem) alone in the treatment of advanced pancreatic cancer: meta-analysis of sixteen randomized trials. J Clin Oncol 25(18S):4515Google Scholar
- 15.Oettle H, Pelezer U, Stieler J (2005) Oxaliplatin/folinic acid/5-fluorouracil [24 h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 23(16S):4031Google Scholar
- 20.Riess H, Helm A, Niedergethmann M et al (2005) A randomized, prospective, multicenter, phase II trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 23(16S):4009Google Scholar
- 21.Poplin E, Levy DE, Berlin J et al (2006) Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 24(18S):4004Google Scholar
- 23.Pelzer U, Kubica K, Stieler J et al (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO003 study. J Clin Oncol 26(15S):4508Google Scholar
- 24.Garnier C, Rebischung C, Chirpaz E et al (2001) Phase II study of a combination with leucovorin (LV), 5 FU bolus and infusion (FU), gemcitabine (GEM) and oxaliplatin (LOHP) (FOLFU GEMOX regimen) in locally advanced (LA) and metastatic (M) pancreatic carcinoma (APC). Proc Am Soc Clin Oncol 20:620Google Scholar
- 26.Ychou M, Desserigne F, Guimbaud R et al (2007) Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial. J Clin Oncol 25(18S):4516Google Scholar
- 27.Verslype C, Van Cutsem E, Dicato M et al (2006) The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol 18(7S):vii1–10Google Scholar
- 29.Rana V, Krishnan S, Abbruzzese JL et al (2006) Neoadjuvant chemotherapy improves outcomes of chemoradiation therapy for locally advanced pancreatic cancer. J Clin Oncol 24(18S):4036Google Scholar
- 30.Chen LT, Ch’ang HJ, Huang CL et al (2008) Safety-profile of gemcitabine-based chemoradiotherapy (CRT) after triplet induction chemotherapy (CT) in locally advanced pancreatic cancer (LAPC): preliminary data from Taiwan Cooperative Oncology Group (TCOG) T1204 study. In: ASCO Gastrointestinal Cancers Symposium, Orlando; abstract 156Google Scholar